White label ELPA - ClinicalTrials.eu

Study on Improving Treatment for Sickle Cell Disease Patients Using Hydroxycarbamide

Not recruiting

3 1 1 1
Investigated Diseases:
- Sickle cell disease
Investigated Drugs:
- Hydroxycarbamide
Study Comparing Lazertinib and Subcutaneous Amivantamab with Intravenous Amivantamab for Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

Not recruiting

3 1 1
Investigated Drugs:
- Lazertinib
- Amivantamab
Study on the Safety and Tolerability of Oral Dersimelagon for Patients with Erythropoietic Protoporphyria or X-Linked Protoporphyria

Not recruiting

3 1 1
Investigated Drugs:
- Dersimelagon Phosphate
+4
Study of RVU120 for Patients with Advanced Solid Tumors After Standard Treatments Have Failed

Not recruiting

2 1 1 1
Investigated Diseases:
- Neoplasm
Investigated Drugs:
- 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Not recruiting

3 1 1
Investigated Diseases:
- Prostate cancer
Investigated Drugs:
- Enzalutamide
- Leuprorelin Acetate
+4
Study on Medical Cannabis Aerosol for Treating Diabetic Nerve Pain in Patients Using Syqe Inhaler

Not recruiting

2 1
Investigated Drugs:
- Cannabis Sativa Flower
Study of Teclistamab with Daratumumab or Lenalidomide for Elderly Patients with Newly Diagnosed Multiple Myeloma

Not recruiting

2 1 1 1
Investigated Drugs:
Study on the Long-Term Safety of Brivaracetam for Children and Young Adults with Childhood or Juvenile Absence Epilepsy

Not recruiting

3 1 1
Investigated Drugs:
- Brivaracetam
Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Not recruiting

3 1 1 1
Investigated Drugs:
+15
Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

Not recruiting

2 1 1
Investigated Drugs:
- Repotrectinib
+3

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies